SCHEMBL6714047

SCHEMBL6714047

COc1cc(C(C)C)ccc1-c1ccc2cc3n(c2c1)CCNCC3

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.45
HTR2C P28335 7/20 0.45
HTR7 P34969 2/20 0.38
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
ACVR1 Q04771 5/20 0.34
TGFBR1 P36897 3/20 0.34
HTR1A P08908 2/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
ADRB1 P08588 1/20 0.33
TLR9 Q9NR96 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713860 0.92 HTR2A (0.45) HTR2AHTR2CHTR7AKR1C3AKR1C2
SCHEMBL6711320 0.86 HTR2A (0.58) HTR2AHTR2CHTR7HTR1AHTR1D
SCHEMBL6712355 0.84 HTR2A (0.56) HTR2AHTR2CHTR7HTR1AUSP2
SCHEMBL6711371 0.83 HTR2A (0.55) HTR2AHTR2CHTR7HTR1A
SCHEMBL6711398 0.79 HTR2A (0.51) HTR2AHTR2CHTR7AKR1C3AKR1C2
SCHEMBL6711539 0.79 HTR2A (0.47) HTR2AHTR2CHTR7ACVR1TGFBR1
SCHEMBL6713801 0.78 HTR2A (0.53) HTR2AHTR2CHTR7ACVR1TGFBR1
SCHEMBL6718341 0.78 HTR2A (0.53) HTR2AHTR2CHTR7ACVR1TGFBR1
SCHEMBL6715798 0.78 HTR2A (0.58) HTR2AHTR2CHTR7ACVR1TGFBR1
SCHEMBL6718656 0.78 HTR2A (0.58) HTR2AHTR2CHTR7HTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US claimed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885HTR7 6/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885HTR7 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.